ReviewGut2015
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
Review in Gut, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.
- Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.World journal of gastroenterology · 2016Pooled it
- Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.PloS one · 2016Trial
- Identification of Rhododendron mariae extraction as a new attachment inhibitor against dengue virus by targeting the envelope protein domain III.Frontiers in immunology · 2025Article
- Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing.Journal of clinical microbiology · 2024Article
- Knowledge, Attitude and Factors associated with Self-efficacy in Screening and Treatment of Hepatitis C among Primary Care Doctors in Selangor.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2024Article
- The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCV-comparable to SMR (standardized mortality ratio) of Japan general population.Hepatology international · 2023Article
- Article
- Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017.Liver international : official journal of the International Association for the Study of the Liver · 2023Article
- Differential immune transcriptomic profiles between vaccinated and resolved HCV reinfected subjects.PLoS pathogens · 2022Article
- Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C.Biomedical reports · 2022Article
- Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C.The Journal of infectious diseases · 2022Article
- Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection.International journal of environmental research and public health · 2022Article
- Apolipoprotein E, a Crucial Cellular Protein in the Lifecycle of Hepatitis Viruses.International journal of molecular sciences · 2022Review
- Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure.Journal of clinical medicine · 2022Review
- Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.Infectious diseases and therapy · 2021Article
- NS5A-ISGylation via Lysine 26 Has a Critical Role for Efficient Propagation of Hepatitis C Virus Genotype 2a.The Kobe journal of medical sciences · 2021Article
- Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis.Hepatology (Baltimore, Md.) · 2021Article
- In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus.PLoS pathogens · 2021Article
- A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection.Frontiers in immunology · 2021Review
- Progress towards elimination goals for viral hepatitis.Nature reviews. Gastroenterology & hepatology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 10 institutions in 6 countries.
Funding
Abstract
Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates reach 90% and above for many patient groups. The new treatments are effective, well tolerated, allow for shorter treatment regimens and offer new opportunities for previously excluded groups. This therapeutic revolution has changed the rules for treatment of HCV, moving the field towards an interferon-free era and raising the prospect of HCV eradication. This manuscript addresses the new challenges regarding treatment optimisation in the real world, improvement of antiviral efficacy in 'hard-to-treat' groups, the management of patients whose direct acting antiviral drug treatment was unsuccessful, and access to diagnosis and treatment in different parts of the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.